B2BROKER
14.12.2021 11:02:59 CET | Business Wire | Press release
B2Broker , a leading technology and liquidity provider within the Forex/CFDs and Digital Currency industries, has confirmed that it has expanded its global reach by establishing a presence in the heavily EU regulated Forex /CFDs market through B2Prime , a Cyprus based Financial Institution authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005172/en/
B2Broker now has a vested interest in B2Prime after fulfilling the necessary legal requirements for the required ownership changes. The new owners of B2Prime are Arthur Azizov, founder of B2Broker Group of Companies and Evgeniya Mykulyak, co-founder of B2Broker Group of Companies. Nick Chrysochos becomes the CEO of B2Prime. The move confirms the group’s commitment to providing its investment related services on a global scale through a Liquidity Provider regulated by one of the most well respected and recognised Financial Market Supervisory Authorities.
About B2Prime
B2Prime is a global regulated Prime of Prime (PoP) Multi-Asset Liquidity Provider for institutional and professional clients across the whole spectrum of the financial markets. Its core investment services consist of leveraged derivative products in CFDs (Forex, metals, commodities, shares, indices and cryptocurrencies).
B2Broker Group of Companies
B2Broker is a global brand with a solid reputation in the B2B sphere as one of the most in-demand technology and liquidity providers for Forex and crypto brokers, crypto exchanges and other financial services entities. The company offers a wide range of services including Crypto/Forex/CFD liquidity, Crypto/Forex Broker turnkey solutions, crypto payment processing (B2BinPay), MT4/5 white label solutions, B2Core (Trader’s Room) , B2Trader (Matching Engine) and liquidity on over 800 trading instruments across the entire spectrum of assets.
Headquartered in Moscow, B2Broker has several years of operational experience with 10 offices in 8 countries across Russia, Europe, Asia and MENA. A total of 7 licences to its name including FCA, AEMI and Central Bank of Russia, allows B2Broker to serve clients across 50 countries, offering Forex liquidity distribution and a range of other services to the Forex, Crypto and Securities industries. The company has secured a large portfolio of well-known global clients in the financial services industry with plans to further increase company representation and visibility across the globe.
What the News Means For Clients
CySEC is Cyprus’ financial regulator which provides a framework within which the country’s licenced financial services firms are obliged to operate. As a CySEC regulated broker, B2Prime must adhere to the strictest financial market regulatory standards, including capital adequacy requirements, segregation of client funds and transparency of business operations.
Clients residing in the EU, UK and several other 3rd country jurisdictions can now be safely onboarded under the EU MiFID II regulatory standards. B2Broker can now expand its footprint in the European Union and provide clients with the opportunity to experience the organisation’s full product and service offering through an EU financial services brokerage licence, while positioning itself on an accelerated global growth path.
B2Broker Group of Companies CEO, Arthur Azizov, commented, “We are delighted that B2Prime has secured CySEC approval. The licence gives us the scope to provide institutional grade liquidity to clients in over 30 countries. Meanwhile, our clients will be able to benefit from an enhanced level of protection, safe in the knowledge that they have the backing of a world-leading, multi-regulated technology and liquidity provider. We expect that having now secured CySEC’s authorisation to provide our investment liquidity services, it will help us establish our place in this space as one of the strongest and most reliable organisations where clients can feel at ease when trading with us”.
B2Prime’s owner and Executive Director, Evgeniya Mykulyak, co-founder of B2Broker Group commented, “My vision is to make B2Prime one of the most solid and reliable financial services companies in the Forex space with a high standard of service provision being our key focus. I look forward to exploring the many new opportunities available to us in Europe and to welcoming new clients on board. Our efforts will include the introduction of new trading platforms for connection as well as the continued rollout of our Prime of Prime liquidity services. We are already building a strong liquidity provision network in the European market and have established relationships with major Prime Brokers. Furthermore, we plan to become a member of several exchanges, all in all, making B2Prime a major player in the financial services industry”.
B2Prime CEO, Nick Chrysochos added, “With Artur Azizov’s long experience and solid credentials in the Forex and Crypto space and Evgeniya Mykulyak’s deep industry know-how and clear vision for the company, we will be able to provide advanced, cutting-edge technology so that our clients can trade with the reassurance of knowing that their trading activities are managed by a reputable firm that adheres to the most stringent regulatory standards of CySEC”.
Final Word
BPrime has already opened the door to receiving new clients and can connect brokers via OneZero, MT5 and PrimeXM platforms to offer trading on 115 Forex pairs including 22 Crypto CFD pairs, Spot Metals, Indices and Spot Energies.
The latest licence acquisition is a part of B2Broker’s overall strategic plan to have a presence in all the major jurisdictions, focusing on the goal of becoming a global liquidity provider. The corresponding launch of commercial operations in Cyprus is also a testament to the company’s ongoing success and growth, where it will continue to provide some of the best liquidity and trading services in the industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005172/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom